Female doctors and pharmacists are using a male version of the same cancer treatment that is used by male patients.
A new male version for male patients, called male ed, is being promoted by the University of California San Francisco Medical Center, which was founded by a man.
The university said the male ed was developed in collaboration with researchers at San Francisco General Hospital and is being used to treat a subset of male patients with primary glioma.
The therapy is not approved for use by women.
It is not a cure, but the therapy could prevent the recurrence of the cancer, said Michael D. Hallett, a professor of medicine at UCSF and the lead author of a study about the therapy.
Hallett said the therapy works best on males with primary aggressive gliomas, those with a 20% or more risk of recurrence.
The study is available online and has been approved by the National Institutes of Health.
The male ed has a slightly different name, male baldness.
It also is used for patients with secondary aggressive glioidomas, which are rare.
The study found that patients who received the male version had a lower risk of death compared with patients who did not receive the male treatment.
But the study did not look at whether the therapy reduced the risk of mortality.
Harena Alizadeh, a research associate in the UCSF Department of Medicine’s Division of Surgery, said that although the male and female versions have different names, they both treat the same cancers.
Alizades said it is important to understand which treatment is right for each patient because treatment options vary from patient to patient.
Halsey said that since the male ED was developed, the U.S. Food and Drug Administration has approved it for use in patients with mild to moderate aggressive gliosidomas.
She said the U,S.
Department of Health and Human Services approved the male-approved treatment for use on those with aggressive glia and lymphoma.
